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ABSTRACT
OBJECTIVES Because of its multifaceted cardioprotective effects, remote ischemic pre-conditioning (RIPC) was
examined as a strategy to attenuate doxorubicin (DOX) cardiotoxicity.
BACKGROUND The use of DOX is limited by dose-dependent cardiotoxicity and heart failure. Oxidative stress, mito-
chondrial dysfunction, inflammation, and autophagy modulation have been proposed as mediators of DOX cardiotoxicity.
METHODS After baseline echocardiography, adult male CD1 mice were randomized to either sham or RIPC protocol
(3 cycles of 5 min femoral artery occlusion followed by 5 min reperfusion) 1 h before receiving DOX (20 mg/kg, intra-
peritoneal). The mice were observed primarily for survival over 85 days (86 mice). An additional cohort of 50 mice was
randomized to either sham or RIPC 1 h before DOX treatment and was followed for 25 days, at which time cardiac fibrosis,
apoptosis, and mitochondrial oxidative phosphorylation were assessed, as well as the expression profiles of apoptosis and
autophagy markers.
RESULTS Survivalwas significantly improved in theRIPC cohort comparedwith the shamcohort (p¼0.007). DOX-induced
cardiac fibrosis and apoptosis were significantly attenuated with RIPC compared with sham (p < 0.05 and p < 0.001,
respectively). Although nomitochondrial dysfunction was detected at 25 days, there was a significant increase in autophagy
markers with DOX that was attenuated with RIPC. Moreover, DOX caused a 49% decline in cardiac BCL2/BAX expression,
which was restored with RIPC (p < 0.05 vs. DOX). DOX also resulted in a 17% reduction in left ventricular mass at 25 days,
which was prevented with RIPC (p < 0.01), despite the lack of significant changes in left ventricular ejection fraction.
CONCLUSIONS Our preclinical results suggested that RIPC before DOX administration might be a promising
approach for attenuating DOX cardiotoxicity. (J Am Coll Cardiol CardioOnc 2019;1:221–34) © 2019 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
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T he use of doxorubicin (DOX), achemotherapeutic antibiotic fromthe anthracycline family, has been
limited by its dose-dependent cardiotoxicity
and related heart failure in cancer survivors
(1,2). Immense research effort has been
focused on attenuating DOX cardiotoxicity
by modulating its cumulative dose or consid-
ering alternative chemotherapies; however,
DOX remains among the most efficacious
agents for a number of cancers, including
solid and hematological malignancies.
Despite careful adjustment of the cumulative
dose, exposure to low or moderate doses of
DOX have been associated with early evi-
dence of subclinical cardiovascular disease (3).
Studies have indicated the involvement of topoisom-
erase IIb inhibition, oxidative stress, mitochondrial
dysfunction, inflammation, and autophagy modula-
tion, among several other factors, for mediating
DOX-induced cardiotoxicity and subsequent cardio-
myopathy (4–8). However, to date, there are no uni-
versally prescribed or widely used preventive or
therapeutic modalities that mitigate DOX cardiotoxic-
ity. Recent statistics based on 3 Phase III clinical trials
estimate that 26% of cancer patients develop cardio-
toxicity after exposure to a cumulative dose of
550 mg/m2 (9), and >50% of all older adult patients
with lymphoma and survivors of childhood cancer
who received DOX treatment remain at high risk of
developing cardiotoxicity (10).
Ischemic pre-conditioning refers to sublethal epi-
sodes of ischemia that prepare an organ or vascular
territory for subsequent prolonged ischemic events
(11,12). Early animal models showed that brief tran-
sient occlusions of a coronary artery could dramati-
cally limit myocardial infarct size following longer
subsequent ischemia (13). Similar efficacy can be
attained when the pre-conditioning event occurs in a
remote vascular bed, a phenomenon known as
remote ischemic pre-conditioning (RIPC) (14–17). The
mechanism by which RIPC (or any ischemic pre-
conditioning) works is not entirely clear and is
almost certainly multifactorial (18).
The purpose of our study was to determine
whether RIPC can limit DOX-induced cardiotoxicity
in a mouse model. We evaluated the impact of RIPC
applied in a clinically feasible time of 1 h before DOX
administration on survival, cardiac function, left
ventricular (LV) mass, cardiac fibrosis, apoptosis, and
autophagy.
METHODS
ANIMALS. Adult male CD1 mice were purchased
from Charles River Laboratories International, Inc.
(Wilmington, Massachusetts). The animal experi-
mental protocols were approved by the Institutional
Animal Care and Use Committee of Virginia
Commonwealth University. All animal experiments
were conducted under the guidelines on humane use
and care of laboratory animals for biomedical
research published by the U.S. National Institutes of
Health (National Institutes of Health Publication No.
85-23, revised 1996).
RIPC AND DOX. Animals were randomized to either
sham control or RIPC protocol (Figure 1). A subgroup
of age-matched naive male CD1 mice (n ¼ 12) that did
not receive RIPC or DOX treatment was used as
negative control. Under anesthesia (pentobarbital
30 mg/kg intraperitoneal), all animals had their right
femoral artery exposed, and a silk suture was passed
around the artery. For RIPC, the femoral artery was
then occluded by tightening the suture. The artery
was occluded for 5 min, then the suture was relaxed
for 5 min, then repeated, for a total of 3 cycles of
occlusion and/or reperfusion. The control animals did
not have the suture tightened. One hour after RIPC or
control, all animals received a single intraperitoneal
injection of DOX 20 mg/kg.
All procedures and data analysis were conducted in
a blinded fashion for the various parameters.
SURVIVAL. Two cohorts were included in this study:
1) a long-term cohort that was monitored for survival
for 85 days following the experimental procedure
(RIPC or sham surgery) and DOX treatment; and 2) a
short-term cohort that was killed after 25 days, for
histological and molecular testing. There were 86
mice in the long-term cohort, randomized in 1:1
fashion to RIPC or sham control. The short-term
cohort included 50 mice, similarly randomized. Sur-
vival rate was determined based on the animals that
survived the experimental protocol starting at re-
covery following RIPC or sham surgery.
ECHOCARDIOGRAPHY. Echocardiography was per-
formed using the Vevo2100 ultrasound system (Vis-
ualSonics, Toronto, Ontario, Canada) as previously
reported (19). For methodology details, please refer to
Supplemental Appendix (20,21).
ASSESSMENT OF LV FIBROSIS. Paraffin-embedded
cardiac tissue sections were stained with picrosirius
red to determine interstitial fibrosis as previously
reported (22).
SEE PAGE 235
ABBR EV I A T I ON S
AND ACRONYMS
ADP = adenosine phosphate
DOX = doxorubicin
LV = left ventricular
LVEF = left ventricular ejection
fraction
RIC = remote ischemic
conditioning
RIPC = remote ischemic
pre-conditioning
ROS = reactive oxygen species
STEMI = ST- segment elevation
myocardial infarction
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ASSESSMENT OF CARDIAC APOPTOSIS. Cardiac
apoptosis was detected using the ApoAlert DNA
Fragmentation Assay Kit (Clontech, Mountain
View, California) that detects nuclear DNA fragmen-
tation. A detailed description can be found in
Supplemental Appendix.
MITOCHONDRIA. Mitochondria were isolated from
adult mouse hearts as previously reported (23,24). A
detailed description can be found in the
Supplemental Appendix.
WESTERN BLOTTING. Cardiac protein extraction was
performed as previously reported (25). Specific details
can be found in the Supplemental Appendix.
STATISTICAL ANALYSIS. Continuous variables are
presented as mean  SD for normally distributed
variables and median (25th to 75th percentiles) for
non-normal variables. Comparisons were made using
a Student’s t-test or Mann-Whitney U test for normal
and non-normal variables as appropriate. Survival
rates are presented by Kaplan-Meier plots, which
were compared using the log-rank test. All tests of
significance were 2-sided, and p < 0.05 was consid-
ered statistically significant. Data were analyzed us-
ing SPSS version 24 (IBM, Armonk, New York).
RESULTS
RIPC IMPROVES SURVIVAL AFTER DOX TREATMENT. Of
the initial 86 mice allocated to the long-term survival
cohort (85 days), 4 did not survive the RIPC or sham
procedures and were excluded. The remaining 82
mice (42 RIPC and 40 sham control mice) were
included in the long-term survival cohort and
received DOX 1 h following RIPC or sham procedure.
Survival was significantly improved in mice subjected
to RIPC (p ¼ 0.04) (Figure 2A). Of the initial 50 mice
allocated to the short-term study cohort (25 days), 2
did not survive the RIPC or sham procedures and
were excluded. The remaining 48 mice (23 RIPC and
25 sham control mice) made up the short-term study
cohort. Similar to the long-term cohort, survival was
significantly improved with RIPC compared with DOX
alone at 25 days after treatment (p ¼ 0.035)
(Figure 2B). When the 2 cohorts were combined, the
survival benefit of RIPC was more pronounced
(p ¼ 0.007) (Figure 2C).
RIPC PREVENTS DOX-INDUCED DECLINE IN LV
MASS. Echocardiographic assessments were con-
ducted in both short- and long-term cohorts. Baseline
left ventricular ejection fraction (LVEF) was similar
between the 2 groups (p ¼ 0.90), did not change at
25 days following DOX treatment (p ¼ 0.83)
(Figure 3A), and remained consistent throughout the
study up to 85 days in the long-term cohort. However,
LV mass declined by 17% in the DOX group, which
was completely blunted in the RIPCþDOX mice at
25 days following DOX treatment (Figure 3B). The
long-axis view of global longitudinal strain rate
FIGURE 1 Animal Randomization Diagram
Consort-style diagram showing animal randomization (1:1) in both sham control (doxorubicin [DOX] alone) and remote ischemic pre-
conditioning (RIPC)þDOX treatment groups. One hour after RIPC or sham control, all animals received a single intraperitoneal injection of
DOX 20 mg/kg. Naive animals did not receive DOX or RIPC. (Top) Chronic cohort (85 days; 86 mice) randomization. (Bottom) Short-term
cohort (25 days; 50 mice) randomization.
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analysis did not show any difference between groups
(Figure 3C). LV dimensions in diastole or systole were
not significantly different at 25 days (Figures 3D
and 3E). Cardiac output was significantly higher in
RIPCþDOX group compared with the DOX-alone
group at 25 days (p ¼ 0.05) (Figure 3F). Additional
cardiac parameter data are presented in Table 1.
RIPC ATTENUATES DOX-INDUCED CARDIAC
FIBROSIS AND APOPTOSIS. DOX treatment resulted
in significant cardiac fibrosis 25 days after adminis-
tration, which was attenuated in mice subjected to
RIPC (p < 0.05) (Figure 4). As expected, in age-
matched naive mice, there was no remarkable car-
diac fibrosis.
Terminal deoxynucleotidyl transferase dUTP nick
end labeling staining was used to assess cardiac
apoptosis in the different groups. DOX significantly
increased the frequency of apoptotic nuclei compared
with the naive group, which was mitigated with RIPC
(p < 0.001) (Figure 5).
DOX OR RIPCDDOX DID NOT ALTER MITOCHONDRIAL
OXIDATIVE PHOSPHORYLATION. The rate of oxidative
phosphorylation was determined in mitochondria
isolated from the hearts of mice from the different
groups. RIPC before DOX treatment did not alter the
protein yield of mitochondria (Table 2). In addition,
there were no differences in the rate of oxidative
phosphorylation between the DOX group and the
RIPCþDOX group using complex I or complex II sub-
strates. The rates of adenosine phosphate (ADP)
stimulated (state 3 respiration), ADP-limited (state 4
respiration), maximal ADP-stimulated state 3 respi-
ration (2 mM ADP), and uncoupled respiration (dini-
trophenol stimulated respiration) were all similar.
These similar rates of uncoupled respiration
confirmed that the electron transport chain was un-
altered and also excluded a functionally significant
defect in the phosphorylation apparatus. The
coupling of respiration as shown by the respiratory
control ratio was also not affected by RIPC.
FIGURE 2 Survival After DOX in Mice With and Without RIPC
Kaplan-Meier curves show survival in DOX-injected mice with RIPC or sham control. (A) Mice in the long-term survival cohort, (B) mice in the short-term cohort,
and (C) includes both long-term and short-term cohorts. Abbreviations in Figure 1.
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Mitochondrial respiration in both treatment groups
was also similar to that in mitochondria from hearts
of the naive cohort at 25 days following treatment.
RIPC ATTENUATES DOX-INDUCED APOPTOTIC AND
AUTOPHAGIC SIGNALING. Cardiac expression of
BCL2 and BAX, well-known indicators of apoptosis,
was evaluated at 25 days following DOX and RIPC
treatment. The results showed that BCL2 expression
was markedly downregulated in DOX-treated mice
(p < 0.05 vs. control subjects; n ¼ 3) (Figure 6A),
whereas RIPC preserved the expression of BCL2
(p < 0.05 vs. DOX). The expression of pro-apoptotic
protein BAX was induced following DOX treatment,
and it was not blunted by RIPC (p > 0.05 vs. control
subjects; n ¼ 3). Nevertheless, the significant 49%
decline in BCL2/BAX ratio illustrated that DOX treat-
ment enhanced pro-apoptotic signaling and that RIPC
significantly restored the ratio to normal levels.
Figure 6B demonstrates a significant decline in
phosphorylated AKT1 by day 25 after DOX treatment,
which was partially preserved with RIPC.
We further investigated and analyzed cardiac
protein expression of Beclin (BECN1), one of the
markers of autophagy, and our data indicated that it
was induced by day 25 following DOX treatment
(p < 0.005 vs. control subjects; n ¼ 3) (Figure 7).
Interestingly, RIPC prevented the DOX-induced in-
crease in Beclin expression (p < 0.005 vs. DOX; n ¼ 3).
Moreover, the induction of the ratio of LC-3-II/I also
confirmed the activation of autophagy with DOX
treatment (p < 0.05 vs. control subjects), whereas
RIPC effectively blunted the induction of the LCII/I
ratio (p < 0.05 vs. DOX; n ¼ 3). However, the
expression level of p62, which is expected to be
reciprocally regulated in relation to LC3, was not
altered with DOX or RIPC.
DISCUSSION
Cardiotoxicity secondary to anthracyclines has been
widely documented for the last 5 decades, but the
mechanism remains poorly understood (10).
Numerous studies have implicated oxidative stress by
reactive oxygen species (ROS) (6), iron
overloadinduced toxicity (26), mitochondrial injury
further perpetuating cardiac damage (7), and topo-
isomerase IIb inhibition and DNA intercalation (4,5)
FIGURE 3 Echocardiographic Parameters 25 Days Post-DOX Treatment With or Without RIPC
(A) Despite no change in left ventricular (LV) ejection fraction at 25 days following DOX treatment in either group, (B) LV mass significantly declined by day 25 following
DOX treatment in the sham group (red) but was preserved with RIPC (blue). (C) Cardiac global strain was not different between groups. No significant differences were
reported in LV diameter in (D) diastole and (E) systole. (F) Cardiac output was higher in RIPCþDOX at 25 days. Data presented as mean  SD. Orange ¼ sham baseline;
green¼RIPC baseline; red¼ ShamþDOX; blue¼RIPCþDOX. AA¼ anterior apical; AB¼ anterior basal; AM¼ anteriormid; PA¼ posterior anterior; PB¼ posterior basal;
PM ¼ posterior mid; other abbreviations as in Figure 1.
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among many other pathways as mechanisms that
mediate DOX cardiotoxicity. However, therapeutic
interventions individually targeting these pathways
have not yielded much success in alleviating the
clinical problem. Although limiting the cumulative
dose of DOX, resorting to liposomal DOX, or use of
dexrazoxane demonstrated some degree of success in
attenuating cardiac injury, cardiovascular mortality
due to cardiac toxicity in cancer survivors still con-
tributes to morbidity and mortality in this patient
population (27). Despite the significant improvements
in developing new chemotherapeutic drugs as well as
small molecule and biological treatment options that
have expanded the life span of cancer survivors,
anthracyclines are still a significant portion of the
chemotherapy of choice for several cancers, including
TABLE 1 Cardiac Physiological Parameters
DOX (n ¼ 18) RIPCþDOX (n ¼ 22) p Value
Baseline 25 Days Baseline 25 Days 25 Days RIPC þ DOX vs. 25 Days DOX
LV mass, mg 115.5  3.9 97.8  4.7 114.6  5.7 105.1  4.6 0.008
LVIDd, mm 4.50  0.01 4.26  0.06 4.38  0.06 4.38  0.09 NS
LVIDs, mm 3.17  0.09 2.68  0.11 3.08  0.08 2.73  0.11 NS
CO, ml/min 21.85  1.12 22.63  1.17 19.26  0.97 25.97  1.43 0.05
LV fibrosis, % N/A 14.61  1.83 N/A 10.60  2.37 <0.001
Time points for LVEF, %
Baseline 57.4  1.2 55.4  1.3 NS
1 week 61.4  1.7 59.0  3.8 NS
2 weeks 61.2  1.6 62.3  1.6 NS
3 weeks 60.6  1.9 60.7  1.8 NS
5 weeks 57.36  4.9 57.4  3.2 NS
9 weeks 59.7  4.3 55.9  1.7 NS
Segments at LAX longitudinal
strain rate at 3 weeks (Pk%s1)
Posterior base 9.3  2.3 8.5  1.2 NS
Posterior mid 7.2  1.0 5.1  0.5 NS
Posterior apex 7.4  0.8 5.9  0.9 NS
Anterior apex 9.0  0.9 8.6  1.0 NS
Anterior mid 8.3  1.1 5.6  0.5 NS
Anterior base 6.0  0.9 4.4  0.7 NS
Values are mean  SD.
CO ¼ cardiac output; DOX ¼ doxorubicin; LAX ¼ long axis; LV ¼ left ventricle; LVIDd ¼ LV internal diameter diastole; LVIDs ¼ LV internal diameter systole; RIPC ¼ remote
ischemic pre-conditioning.
TABLE 2 Remote Pre-Conditioning Did Not Alter Respiration in Isolated Cardiac Mitochondria at 25 Days
Control Naive (n ¼ 5) DOX (n ¼ 6) RIPCþDOX (n ¼ 6)
Complex I substrates: glutamate þ malate
Protein yield (mg/g heart tissue) 27.4 (27.1–28.2) 27.2 (26.3–28.3) 26.2 (25.6–26.6)
State 3 (ADP stimulated) 443 (438.0–473.0) 507.5 (464.5–537.0) 446.0 (473.3–481.0)
State 4 (ADP limited) 54.0 (47.0–62.0) 62.0 (57.5–65.8) 61.5 (56.5–65.8)
RCR 8.0 (7.9–9.4) 8.0 (7.9–8.5) 7.7 (7.2–8.0)
2-mM ADP 604.0 (576.0–604.0) 596.5 (551.3–602.8) 522.0 (515.0–583.8)
DNP stimulated 567.0 (532.0–575.0) 574.0 (516.5–603.8) 503.0 (594.0–540.5)
Complex II substrates: succinate
State 3 (ADP stimulated) 894.0 (854.0–923.0) 817.0 (795.3–862.0) 830.0 (787.0–875.3)
State 4 (ADP limited) 222.0 (213.0–240.0) 230.5 (186.5–255.0) 233.5 (218.3–244.3)
RCR 3.8 (3.8–3.9) 3.5 (3.3–3.6) 3.4 (3.3–3.6)
2-mM ADP 872.0 (806.0–872.0) 792.5 (729.8–815.5) 784.0 (711.5–846.8)
DNP stimulated 729.0 (715.0–758.0) 678.0 (602.8–720.3) 729.5 (650.5–803.3)
Values are median (interquartile range).
ADP ¼ adenosine diphosphate; DNP ¼ dinitrophenol; RCR ¼ respiratory control ratio; other abbreviation as in Table 1.
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lymphoma in older adults, childhood cancer, and
patients with breast cancer (28–31). This information
motivates investigations into cardioprotective stra-
tegies that are multifaceted to encompass the known
and rather unknown aspects and mechanisms of DOX
cardiotoxicity (Central Illustration).
Myocardial ischemic pre-conditioning was first
described by Murry et al. (11,12) in the mid-1980s and
was inspired by the cardiac warmup phenomenon
that cardiologists had been observing in patients with
a history of angina who subsequently experienced
myocardial infarction. The hypothesis behind the
initial preclinical studies was that repeated cycles of
short-lived or nonlethal ischemia and reperfusion by
way of coronary artery occlusion and/or reflow would
activate protective mechanisms that warn the heart
about subsequent prolonged or lethal ischemia,
thereby attenuating a host of pathological signaling
that leads to oxidative stress, inflammation, mito-
chondrial dysfunction, and several modalities of cell
death (32). This phenomenon was also shown to exert
protective effects in other organs in the experimental
setting, including the brain, liver, and kidneys. Not
only was ischemic pre-conditioning protective when
applied to the same organ that subsequently experi-
enced sustained ischemia, but bouts of ischemia and
reperfusion that affected a vascular bed remote from
the heart, also known as RIPC, were shown to also
protect the heart and other organs against sustained
subsequent ischemia (14–17). The mechanism(s) of
action of RIPC seem(s) to involve multiple pathways
implicated in ischemic pre-conditioning in addition
to some newly identified circulating factors,
including exosomes and micro-RNAs (33–35). Mito-
chondrial damage during myocardial ischemia
perpetuated the production of ROS at the onset of
FIGURE 4 Cardiac Fibrosis 25 Days Post-DOX Treatment
Picrosirius red staining of heart sections showed significant fibrosis by 25 days following DOX treatment compared with naive control hearts, which was significantly
attenuated with RIPC. Data presented as mean  SD. DOX (red circles), RIPCþDOX (blue squares), naive (green triangles). Abbreviations as in Figures 1 and 2.
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FIGURE 5 Cardiac Apoptosis on Day 25 Following DOX Treatment
Terminal deoxynucleotidyl transferase dUTP nick end labeling staining demonstrating significant attenuation of cardiac apoptosis in RIPCþDOX group compared with
DOX group, which was significantly higher than naive control hearts. Data presented as mean  SD. DOX (red circles), RIPCþDOX (blue squares), naive (green tri-
angles). Arrows indicate apoptotic nuclei. Groups as noted in Figure 1.
FIGURE 6 Cardiac Proapoptotic and Antiapoptotic Protein Expression and AKT1 Survival Signaling 25 Days Following DOX Treatment
(A) Western blot analysis revealed a significant decline in BCL2/BAX ratio with DOX, indicating pro-apoptotic signaling that was blunted with RIPC. (B) Pro-survival
AKT1 phosphorylation was also significantly decreased with DOX but was partially preserved with RIPC. Data presented as mean  SD. DOX (red circles), RIPCþDOX
(blue squares), naive (green triangles). Abbreviations as in Figure 1.
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reperfusion due to damage incurred in the electron
transport chain (36). Ischemic pre-conditioning, due
to upregulation of several antioxidant proteins, was
effective in attenuating oxidative stress and reducing
cardiac injury following ischemia (37). Among several
observed modalities of cell death in the context of
ischemiareperfusion injury and DOX cardiotoxicity,
ferroptosis was a key mechanism downstream of
excessive ROS production and iron overload (26).
ROS-induced oxidation of membrane lipids was
shown to increase free iron levels—an effect that was
mitigated by pre-conditioning before inducing
ischemia/reperfusion in rats (38).
Because of the similarity of pathological signaling
between ischemia/reperfusion injury and DOX car-
diotoxicity, the present study evaluated the potential
protective effect of RIPC against DOX cardiotoxicity
in mice (37,39). Our data demonstrated significant
reduction in mortality up to 85 days post-DOX
administration (p ¼ 0.007), which was associated
with attenuation of a decrease in LV mass (p ¼ 0.008),
despite a lack of significant changes in LVEF. DOX-
induced cardiac fibrosis and apoptosis were also
significantly mitigated by RIPC (p < 0.05 vs. DOX).
These changes were also accompanied by attenuation
of apoptosis, as well as autophagy signaling markers
with RIPC compared with DOX. The persistent in-
crease in autophagy markers by day 25 following DOX
treatment could indicate enduring damage that ne-
cessitates removal of impaired components by the
cell, which was not needed in the RIPC cohort. The
attenuation of cardiac fibrosis and apoptosis indi-
cated prevention of different modalities of cell death,
which was suspected to occur over time and ulti-
mately led to cardiomyopathy. Because apoptosis is
the predominant method of cell death with DOX, our
data, which demonstrated a decline in LV mass with
DOX, were in line with clinical data in the literature
and the ability of RIPC to mitigate apoptosis. Its
signaling might explain the preservation of LV mass
with this treatment (40). Although DOX-induced
mitochondrial dysfunction was implicated in several
previous studies, our results suggested that RIPC did
not markedly affect mitochondrial function in the
DOX-treated mice, at least at the time point consid-
ered in this study, which only took into account mice
that survived for 3 weeks after DOX treatment. More
comprehensive assessment of mitochondrial function
FIGURE 7 Autophagy Signaling in the Heart 25 Days Post-DOX Administration
Autophagy markers Beclin (BECN1) and LC3-II/I were significantly increased by day 25 after DOX treatment, which was abrogated with RIPC. No changes were observed
in p62 expression at this time point. Data presented as mean  SD. DOX (red circles), RIPC þDOX (blue squares), naive (green triangles). Abbreviations as in Figure 1.
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at earlier time points following DOX treatment is
warranted.
Several studies in the literature evaluated the po-
tential benefits of RIPC in clinical settings, which
were recently summarized in a meta-analysis of ran-
domized trials on remote ischemic conditioning (RIC)
during primary percutaneous coronary intervention
in patients with ST-segment elevation myocardial
infarction (STEMI) (41). The analysis included 8 ran-
domized trials with 1,083 patients with STEMI who
underwent primary percutaneous coronary interven-
tion with RIC and standard of care versus percuta-
neous coronary intervention with standard of care
only. RIC significantly reduced infarct size measured
by biomarker release (p ¼ 0.001), improved ST-
segment resolution (p < 0.001), attenuated major
adverse cardiac and cerebrovascular events
(p ¼ 0.003), and caused a nonsignificant decrease in
infarct size assessed by cardiac imaging (p ¼ 0.36).
Because most of the evaluated outcomes favored RIC,
the investigators concluded that RIC might improve
cardiovascular outcomes in patients with STEMI. In
addition to the potential benefits of RIPC in the
context of myocardial ischemia, sepsis (35), and cor-
onary artery bypass graft surgery (42), preclinical
studies also indicated that ischemic pre-conditioning
protected cardiomyocytes against DOX-induced
toxicity through a mechanism involving PI3K (39).
Our data indicated a decrease in cardiac AKT1
phosphorylation in the DOX-sham group, which was
partially preserved with RIPC. In addition, several
mechanisms that were shown to mediate DOX
toxicity in the heart and cardiomyocytes were also
regulated by RIPC, including micro-RNA-21, soluble
guanylate cyclase activity, protein kinase G, and Sirt3,
among others (43–46).
This knowledge led to the design of the ERIC-ONC
(Effect of Remote Ischemic Conditioning in Oncology;
NCT02471885) trial (47), which is ongoing. This
is a single-center, blinded, randomized, sham-
controlled study that aims to enroll 128 adult
oncology patients who will receive anthracycline-
based chemotherapy. The patients will be random-
ized in a 1:1 ratio to sham or RIPC with 4 cycles of
5-min upper arm blood pressure cuff inflation and/or
deflation immediately before receiving chemotherapy
throughout the treatment regimen. The primary
endpoint will be high-sensitivity troponin T levels
over 6 cycles of chemotherapy with follow-up at
12 months. Secondary endpoints will include
clinical, electrical (incidence of arrhythmias), struc-
tural (echocardiography to assess function), and
biochemical parameters (mitochondrial DNA,
micro-RNA, and proteomics). This effort is among
the few nonpharmacological attempts to combat
DOX cardiotoxicity. Other clinical trials with
pharmacotherapy-based approaches to date included
the randomized controlled CECCY (Carvedilol Effect
CENTRAL ILLUSTRATION Remote Ischemic Pre-Conditioning Against DOX Cardiotoxicity
Gertz, Z.M. et al. J Am Coll Cardiol CardioOnc. 2019;1(2):221–34.
Key outcomes of improved survival, attenuation of left ventricular (LV) mass decline and mitigation of fibrosis. DOX ¼ doxorubicin.
Gertz et al. J A C C : C A R D I O O N C O L O G Y , V O L . 1 , N O . 2 , 2 0 1 9
RIPC Protects Against DOX Cardiotoxicity D E C E M B E R 2 0 1 9 : 2 2 1 – 3 4
230
FIGURE 8 RIPC Against DOX Cardiotoxicity: Clinical Trial Design
The design of the clinical trial is also included to demonstrate the translational bench-to-bedside efforts at Virginia Commonwealth University. MRI ¼ magnetic
resonance imaging.
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in Preventing Chemotherapy-Induced Cardiotoxicity)
trial, which involved 200 patients and demonstrated
a significant reduction in diastolic dysfunction and
troponin I levels over time in breast cancer patients
who were treated with carvedilol while receiving
anthracycline chemotherapy (48). The OVERCOME
(Prevention of the Left Ventricular Dysfunction With
Enalapril and Carvedilol in Patients Submitted to
Intensive Chemotherapy for the Treatment of Malig-
nant Hemopathies) trial tested the combination of
angiotensin-converting enzyme inhibitors and car-
vedilol in 90 patients. This trial took advantage of
functional assessment using cardiac magnetic reso-
nance in addition to transthoracic echocardiography
as a primary endpoint (49). The outcomes of this
study indicated that prompt combined treatment
with angiotensin-converting enzyme inhibitors and
ß-blockers might prevent LV systolic dysfunction in
patients with malignant hemopathies who receive
intensive chemotherapy. In this context, an inter-
esting study by Cardinale et al. (50) demonstrated
that prompt initiation of treatment played an impor-
tant role in the extent of LV functional recovery. A
remarkable observation in this study was that most
(98%) cases associated with significant decline in LV
function (reduction in LVEF between 10% and 50%)
occurred in the first 12 months after DOX treatment,
which highlighted the importance of early detection
and timely intervention for best functional recovery
outcomes. This group also noted that strategies that
targeted prevention of DOX cardiotoxicity would be
preferred, rather than treatment of an established
cardiomyopathy that is progressive and may less
likely be reversible after surpassing a certain
threshold (51). To this end, the application of RIPC
immediately before DOX administration, as was the
case in the present study, might prove more prom-
ising than interventions that are applied later in the
course of cardiac dysfunction. Moreover, RIPC is a
noninvasive and safe approach that has been shown
to protect multiple organs, including the heart against
severe ischemia and lung injury after pulmonary
resection in cancer patients (15,52).
STUDY LIMITATIONS. Our study provided proof of
concept that supported the notion of cardioprotection
against DOX toxicity with RIPC. Despite the benefits
reported, there remain some limitations with regard
to the intraperitoneal administration of a single
high dose of DOX in our study. Although this
administration route did not resemble the clinical
approach, it was consistent with numerous pre-
clinical studies in mice and rats, and therefore, was
helpful for comparison with other study outcomes.
We decided to apply RIPC 1 h before DOX injection
based on the known window of protection offered by
RIPC and the practicality or feasibility of this time
point in the clinical setting. However, further studies
are needed to refine the time of intervention, because
the efficacy of RIPC was documented starting from
5 min and lasting up to 72 h (53,54).
Another limitation was that our study focused on
male mice that were healthy (i.e., free of cancer and
cardiovascular risk factors). This was particularly
important because RIPC failed to reduce myocardial
infarct size in the Zucker fatty rat model of type 2
diabetes due to a lack of humoral communication
(55). This might have important implications for
cancer patients with type 2 diabetes and warrants
more in-depth research that also includes female
mice, cancer models, and cardiovascular risk factors.
Studying the effects of RIPC in a tumor-bearing
mouse model is also needed to provide in-depth un-
derstanding regarding the effects of RIPC not only on
the heart, but also on DOX efficacy, if any.
CONCLUSIONS
The application of RIPC 1 h before DOX administra-
tion in adult male mice attenuated mortality, LV mass
decline, cardiac fibrosis, apoptosis, and autophagy
signaling. These findings suggest that, with further
study, RIPC might prevent or attenuate DOX car-
diotoxicity and provide an affordable and noninva-
sive cardioprotective strategy. The impact of DOX on
cardiac mitochondria should be further addressed
with evaluation of mitochondrial oxidative phos-
phorylation and overall integrity at earlier time
points in DOX-treated animals. Based on our data and
the findings reported in the literature, we designed a
single-center clinical trial to test RIPC for prevention
of anthracycline-related cardiotoxicity (Central
Illustration, Figure 8). In terms of patient selection,
chemotherapeutic regimen, and RIPC protocol, our
study design was similar to the ERIC-ONC study (47).
However, although the ERIC-ONC study proposed to
use cardiac troponin change as the primary outcome,
our study uses cardiac magnetic resonance imaging to
evaluate changes in LV function as the primary
outcome (56). Its high reproducibility makes it an
excellent modality for monitoring response to pro-
tective interventions against chemotherapy-induced
cardiotoxicity (57), such as that in our proposed trial.
ADDRESS FOR CORRESPONDENCE: Dr. Fadi N. Sal-
loum, Virginia Commonwealth University, Division of
Cardiology, Box 980204, 1101 East Marshall Street, Room
7-070, Richmond, Virginia 23298. E-mail: fadi.salloum@
vcuhealth.org. Twitter: @SALLOUMFN, @VCUHealth.
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